Livforsakringsbolaget Skandia, Omsesidigt 13F: Cuts MCK Stake by $14M

Livforsakringsbolaget Skandia cut its stake in McKesson Corporation (NYSE:MCK) during the quarter, according to a Form 13F filing with the SEC on October 21, 2026. The fund sold 16,800 shares, marking a 64.4% reduction from its previous holding of 26,082 shares. At the filing date, the remaining 9,282 shares were worth about $7.8 million.

MCK McKesson Corporation

$1,015.50 ▲ +23.70% year to date

1M 3M YTD

Daily close · Oct 21, 2026

What Changed in Livforsakringsbolaget Skandia's McKesson Position

The fund's reduction brought its position down significantly from 26,082 shares to 9,282 shares. McKesson closed at $1,015.50 on the October 21, 2026 filing date.

Other Institutional Activity in McKesson

Other large funds also adjusted their holdings in the medical distributor recently. Franklin Resources, Inc. reduced its holdings by 158,060 shares, ending with 2,905,114 shares worth about $3.0 billion. Massachusetts Financial Services Co. trimmed its stake by 15.7%, selling 453,894 shares to finish with 2,446,386 shares valued at about $2.5 billion.

McKesson Corporation Stock Up 1.2%

McKesson recently traded around $1,030.12 as of October 22, 2026, putting the stock up about 1.4% compared to its $1,015.50 close on the filing date. The stock carries a market capitalization of roughly $117.8 billion and trades with a P/E ratio of 27.1. Its shares sit well above their 50-day moving average of $899.25 and 200-day moving average of $854.92, near the upper end of their 52-week range.

Recent Earnings

For its trailing twelve months, McKesson generated $411.0 billion in revenue and reported earnings of $37.31 per share. The company operates across multiple sectors in healthcare, supplying pharmaceuticals and medical-surgical products. The next earnings report is scheduled for November 4, 2026.

Dividend

McKesson pays an annual dividend of $3.76 per share, which translates to a dividend yield of 0.37%. The company allocates a modest 8.8% of its earnings toward dividend payouts.

Insider Buying and Selling at McKesson Corporation

Company insiders executed several transactions prior to the filing. Chief Executive Officer Brian Scott Tyler sold 8,463 shares on July 7, 2026, at an average price of $793.56 for a total value of $6.7 million. Director Bradley E. Lerman sold 301 shares on August 10, 2026, at $892.32 per share. Officer Napoleon B. Rutledge Jr. disposed of 111 shares on September 8, 2026, at $891.45 per share. Finally, Chief Technology Officer Francisco Fraga sold 800 shares on October 15, 2026, at $995.80 per share.

Analysts Set New Price Targets

Wall Street firms frequently review their targets for the healthcare distributor. On August 19, 2026, Barclays maintained its Overweight rating while lifting its target from $925.00 to $1,000.00. RBC Capital reiterated a Sector Perform rating with an $845.00 target on September 14, 2026. Leerink Partners maintained an Outperform rating on October 7, 2026, raising its target from $1,030.00 to $1,070.00. UBS maintained a Buy rating on October 16, 2026, increasing its target from $1,080.00 to $1,200.00. Mizuho maintained a Neutral rating on October 20, 2026, bumping its target from $905.00 to $1,020.00. Across the broader analyst community, the stock holds a consensus buy rating with a mean price target of $1,001.43 based on 14 analyst opinions.

About McKesson

Headquartered in Irving, Texas, McKesson Corporation operates as a key player in healthcare logistics and distribution. The firm manages large-scale supply chains for pharmaceuticals, oncology products, and medical-surgical supplies across North America and international markets.

Bottom Line

Investors will look toward McKesson's upcoming earnings release on November 4, 2026, for fresh insights into the company's financial performance. Monitoring subsequent institutional filings will show whether other large shareholders follow Skandia's lead in trimming their positions.